Merck KGaA could soon be announcing new partnership deals to help finance its promising drug development pipeline.
According to a report in Reuters, the German drugmaker could specifically use partnerships to continue its development of evobrutinib, an autoimmune disease treatment, and M7842, a cancer medication it is currently testing in comparison to the blockbuster Keytruda.
Despite the positive results from trials of both medications, Merck is reportedly looking for financing help to offset losses in operating profit from its high-tech chemicals division.
Both medications have moved into phase 2 trials.
Read the full Reuters report.